StockData
Estrella Immunopharma, Inc. logo

Estrella Immunopharma, Inc. (ESLAW) revenue by segment

ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-2.08%)

Close on Nov 18, 2026Market cap $14.48MP/E –Yield –

Estrella Immunopharma, Inc. revenue by segment

No segment breakdown reported

Estrella Immunopharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.

See a number that looks wrong?